ESTRO 2021 Abstract Book

S251

ESTRO 2021

Conclusion Patients receiving (neo)adjuvant chemotherapy experience significantly more often grade 1-2 toxicity, but not grade 3 toxicity, in the first 6-12 months after surgery compared to patients in the STD- group. Thereafter, toxicity decreases over time and is not statistically different between the groups. The results demonstrate that pre-operative short-course radiotherapy and chemotherapy is a superior treatment; DrTF and pCR are improved and it does not result in worse HRQL, functional outcome or more grade ≥3 toxicity compared to standard chemoradiotherapy. It should therefore be discussed with LARC patients as a valuable option. OC-0338 Prognostic value of testosterone following androgen deprivation and high-dose radiotherapy in prostate cancer A. Zapatero 1 , A. Guerrero 2 , X. Maldonado 3 , A. Alvarez 4 , C. González San Segundo 5 , M.A. Cabeza Rodríguez 6 , C. Martin de Vidales 1 , J.M. Sole 7 , A. Pedro Olivé 8 , F. Casas 9 , A. Boladeras 10 , M.L. Vázquez de la Torre 11 , F.A. Calvo 5 1 Hospital Universitario de La Princesa, Radiation Oncology, Madrid, Spain; 2 Hospital Son Espases, Radiation Oncology, Palma de Mallorca, Spain; 3 Hospital Universitari Vall d'Hebron, Radiation Oncology, Barcelona, Spain; 4 Hospital General Universitario Gregorio Marañón, Radiation Oncologyy, Madrid, Spain; 5 Hospital General Universitario Gregorio Marañón, Radiation Oncology, Madrid, Spain; 6 Hospital Universitario 12 de Octubre, Radiation Oncology, Madrid, Spain; 7 Hospital General de Catalunya, Radiation Oncology, Barcelona,